DURHAM, N.C., Oct. 18 /PRNewswire/ -- Serenex, Inc., an integrated oncology-focused drug discovery and development company, announced that Dr. Richard Kent, Chief Executive Officer, is scheduled to present today at the BIO InvestorForum taking place at the Palace Hotel in San Francisco. During the presentation, which will be web cast, Dr. Kent will provide an overview of the company and its ongoing development programs. Specifically, Dr. Kent will review SNX-1012, the company's phase 2 compound for oral mucositis and SNX-5422, the company's novel Hsp90 inhibitor candidate. A replay of the presentation will be available under the "News" section of the Serenex website at http://www.serenex.com.
The following are specific details of the conference: BIO InvestorForum: Date: October 18, 2006 Time: 4:40 pm Location: Palace Hotel, 2 New Montgomery Street, San Francisco, CA Room: Presidio Breakout: State Suite 238 About Serenex
Serenex is an integrated oncology-focused drug discovery and development company. The company's mission is to improve the lives of cancer patients by developing proprietary therapeutic and supportive care products. Serenex's lead program, SNX-1012, a product for chemotherapy and radiation-induced oral mucositis, is scheduled to complete phase 2 clinical trials in early 2007. Additionally, Serenex has a pre-clinical program comprising a series of orally bioavailable, small molecule inhibitors of Heat Shock Protein 90 (Hsp90). SNX- 5422, Serenex's lead candidate in this program is scheduled to begin clinical trials in early 2007. Serenex's pipeline is powered by a proprietary screening platform which enables the company to profile compounds, in high throughput, against thousands of important therapeutic and toxicity targets simultaneously. Website: www.serenex.com.
Serenex, Inc.CONTACT: Ian Howes, CFO & Sr. V.P. Corporate Development, Serenex, Inc.,+1-919-281-6031, ihowes@serenex.com; Michelle Linn, Linnden Communications,+1-508-419-1555, linnmich@comcast.net
